Anti‐PD‐1/CTLA‐4 bispecific antibody‐based combination therapy for cervical cancer: a multicenter study with biomarker analysis
Background Cadonilimab is a PD‐1/CTLA‐4 bispecific antibody with robust activity in platinum‐pretreated advanced cervical cancer, while its first‐line value and resistance mechanisms remain unclear. Methods This multicenter retrospective study enrolled 52 treatment‐naive patients with recurrent/metastatic cervical canc...